title: Effect of cerebrolysin on dopaminergic neurodegeneration of rat with oxidative stress induced by 3-nitropropionic acid.
abstract: The study tested the hypothesis that cerebrolysin protects the brain from free radicals in rats treated with 3-nitropropionic acid (3-NPA). To address this hypothesis, the levels of dopamine (DA) and some oxidative stress biomarkers were measured after administration of 3-NPA. Young male Fischer rats were treated for three days with cerebrolysin, 3-NPA or both substances. Their brains were extracted, and DA, lipid peroxidation (LP), glutathione (GSH), calcium, and H2O2 were measured using validated methods. In the cortex, hemispheres and cerebellum/medulla oblongata of the group treated with cerebrolysin and 3-NPA, the levels of DA and LP decreased. In addition, calcium and H2O2 levels decreased in the hemispheres of the same group, while GSH increased in cortex. The increased dopamine metabolism due to the administration of cerebrolysin led to increased formation of radical species and oxidative stress, especially when free radicals were generated by 3-NPA.
authors.forename: David
authors.initials: D
authors.lastname: Calderón Guzmán
authors.forename: Norma Osnaya
authors.initials: NO
authors.lastname: Brizuela
authors.forename: Maribel
authors.initials: M
authors.lastname: Ortíz Herrera
authors.forename: Ernestina
authors.initials: E
authors.lastname: Hernández García
authors.forename: Gerardo
authors.initials: G
authors.lastname: Barragán Mejía
authors.forename: Hugo
authors.initials: H
authors.lastname: Juárez Olguín
authors.forename: Armando
authors.initials: A
authors.lastname: Valenzuela Peraza
authors.forename: Jonas
authors.initials: J
authors.lastname: Attilus
authors.forename: Norma
authors.initials: N
authors.lastname: Labra Ruíz
mesh_terms: D000596:Amino Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D002525:Cerebellar Cortex / Q000187:drug effects / Q000378:metabolism; D002531:Cerebellum / Q000187:drug effects / Q000378:metabolism; D054022:Cerebrum / Q000187:drug effects / Q000378:metabolism; D003292:Convulsants / Q000009:adverse effects; D004298:Dopamine / Q000378:metabolism; D059290:Dopaminergic Neurons / Q000187:drug effects* / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000378:metabolism / Q000517:prevention & control*; D009574:Nitro Compounds / Q000009:adverse effects; D018384:Oxidative Stress / Q000187:drug effects*; D011422:Propionates / Q000009:adverse effects; D011916:Rats, Inbred F344
chemical_list: D000596:Amino Acids; D000975:Antioxidants; D003292:Convulsants; D018696:Neuroprotective Agents; D009574:Nitro Compounds; D011422:Propionates; C006952:cerebrolysin; D005978:Glutathione; C015392:3-nitropropionic acid; D002118:Calcium; D004298:Dopamine